{"entity":{"id":"nct07365995","kind":"trial","name":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer","aka":[],"tldr":"A phase 3 trial testing BNT324 in prostate cancer, now recruiting.","summary":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer is a phase 3 interventional study registered as NCT07365995, led by BioNTech SE with BioNTech (Shanghai) Pharmaceuticals and DualityBio, and recruiting on the registry. Official title: A Phase III, Randomised, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer. Planned enrolment is 736 participants (estimated). The study started in 2026-04-22 and primary completion is expected in 2031-02. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07365995","url":"https://clinicaltrials.gov/study/NCT07365995"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["bnt324"],"companies":["biontech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07365995","phase":"3","setting":"A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer","sponsor":"BioNTech SE","participation":[{"nct":"NCT07365995","source":"https://clinicaltrials.gov/study/NCT07365995","fetchedAt":"2026-10-07T16:55:42.201Z","studySha256":"563e843c8253aed7dcea80ec80b712e753f4b064377c7c9fcc3a47f5d2c382f1","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-18","leadSponsor":"BioNTech SE","collaboratorCount":2,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":736,"enrolmentType":"ESTIMATED","siteCount":33,"recruitingSiteCount":33,"countries":["Australia","China","United Kingdom","United States"]}],"started":"2026-04-22","startedType":"actual","enrolled":736,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07365995/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"bnt324","kind":"drug","name":"BNT324","route":"/drugs/bnt324/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"}]}}